ICUI

Health Technology
$135.39 -2.51%
Back to Screener
Live Volume
296,549
Market Cap
3.38 B
P/E Ratio
73.11
52W Peak Proximity
%84

ANALYSIS CENTER

AI Rating & Analysis: ICUI stock analysis with hallucination-free AI screener tools — real-time price, volume, P/E ratio, 52-week proximity and sector performance data for Health Technology. AI-powered stock analysis and research platform.
GOD-TIER PROMPT ACTIVE
Investment report at Goldman Sachs + Bridgewater + Renaissance Technologies level
10 sections: Tables • Charts • Bullet Points. Plain text PROHIBITED.
1Executive Summary
2Fair Value
3Fundamental Analysis
4Technical Analysis
5Scenario Analysis
6Competitor Comparison
7Dividend Return
8Risk Analysis
9Catalyst Calendar
10Action Plan
HOW IT WORKS: When you click an AI button below, this prompt is instantly copied to your clipboard. Simply Paste (CTRL+V) it into the chat box of the opened AI assistant to run the analysis.
İpucu: Tip: Use our TradingView charts for technical analysis. Evaluate alongside the AI report.
Open Advanced Chart
TradingView Charts
• 15-min delayed price feed • 100+ technical indicators • Sub-second updates • Professional drawing tools
Affiliate links — DocuRefinery may earn a commission when you open an account.

Interactive Brokers

SEC, FINRA, FCA, ASIC Regulation $0 Min. Deposit
Access 150+ global markets. Stocks, ETFs, Options, Futures, Forex.
Open Account

TD Ameritrade (Schwab)

SEC, FINRA Regulation $0 Min. Deposit
Industry-leading trading platforms and comprehensive education.
Open Account
All investing involves risk, including the possible loss of principal. Past performance does not guarantee future results.

Latest News — ICUI

ICU Medical, Inc. — Company Profile & Analysis

ICU Medical, Inc., headquartered in San Clemente, California, was founded in 1984 with a singular mission to improve patient safety and clinical outcomes through innovative medical technology. Since its inception, the company has evolved from a specialized manufacturer of needle-free connectors into a global powerhouse in the infusion therapy and critical care sectors. By consistently focusing on the intersection of patient safety and operational efficiency, ICU Medical has established itself as a critical partner for healthcare providers, ensuring that life-saving medications and fluids are delivered with precision and reliability. The company’s history is marked by strategic growth and a commitment to solving complex clinical challenges, positioning it as a cornerstone of modern hospital infrastructure.

The company’s extensive product portfolio encompasses a wide array of medical solutions, including its flagship Clave needle-free connectors, ChemoLock closed-system transfer devices for hazardous drug handling, and a comprehensive suite of infusion pumps such as the Plum 360. Beyond hardware, ICU Medical excels in the development of sophisticated medication safety software like ICU Medical MedNet, which integrates seamlessly with hospital systems to reduce medication errors. Their offerings also extend to vascular access, anesthesia, and respiratory care, featuring advanced hemodynamic monitoring and temperature management solutions. By integrating hardware with intelligent software, the company provides a holistic ecosystem that supports clinicians throughout the entire infusion and critical care process.

ICU Medical maintains a robust global presence, serving a diverse clientele that includes acute care hospitals, ambulatory clinics, wholesalers, and long-term care facilities. Its market position is bolstered by a deep understanding of the regulatory and clinical requirements of the healthcare industry, allowing it to navigate complex international markets effectively. By targeting both large-scale hospital networks and specialized outpatient facilities, the company ensures a steady demand for its essential medical consumables and capital equipment. This broad reach not only diversifies its revenue streams but also reinforces its reputation as a trusted provider of high-quality, life-critical medical devices across various healthcare settings.

Looking toward the future, ICU Medical is strategically positioned to capitalize on the increasing demand for integrated, data-driven healthcare solutions. The company continues to invest heavily in research and development to enhance its digital health offerings and expand its portfolio of high-acuity medical devices. By focusing on the convergence of infusion hardware and enterprise-class medication management software, ICU Medical aims to lead the transition toward smarter, safer hospital environments. As the healthcare industry shifts toward value-based care, the company’s focus on reducing clinical errors and improving patient outcomes remains a central pillar of its long-term growth strategy and competitive differentiation.

Economic Moat ICU Medical benefits from a significant economic moat driven by high switching costs associated with its integrated infusion pump and software ecosystems, which are deeply embedded in hospital workflows. Furthermore, its extensive portfolio of proprietary, FDA-cleared medical consumables creates a recurring revenue stream that is protected by strong intellectual property and long-standing relationships with major healthcare procurement networks.
CEO Mr. Vivek Jain
Employees 13,000
Headquarters United States
Market Competitors
Smart Tags
#ICUMedical #InfusionTherapy #MedTech #HealthcareInnovation #NASDAQ #PatientSafety #CriticalCare

Market Insights & Investor Q&A — ICUI

Frequently Asked Questions

Is there an instant free AI prompt for analyzing the ICUI stock?
Yes, DocuRefinery offers a no registration, ready-made AI prompt that runs instantly. It uses verified data to scan ICUI and delivers a hallucination-free report in seconds.
How does an AI‑powered anomaly finder work for ICUI?
The anomaly finder scans receivables and balance‑sheet items, flags unusual patterns, and provides an objective, instant analysis. Users simply input a template and receive a verified, no‑signup result.
Can I use a ready-made template for portfolio rebalancing that includes ICUI?
DocuRefinery provides a free, no‑registration portfolio rebalancing template that updates with real data. It instantly adjusts holdings, including ICUI, to maintain optimal allocation.

Deep Analysis

AI‑Enabled Ready Solutions for ICUI Investment Analysis

Modern AI methods bring a new level of precision to ICUI stock analysis, from risk assessment to trend detection. Automated balance‑sheet scans and instant anomaly detection let investors move beyond manual spreadsheet work to faster, data‑driven insights.

DocuRefinery’s platform lets users run deep analyses with a single prompt, no coding required. Ready‑made templates pull verified data in real time, delivering instant, hallucination‑free results that save time and reduce errors.

Traditional analysis can take hours or days to gather data and build models. An AI‑driven, ready‑made prompt approach compresses this into seconds, giving investors a quicker, more objective view of ICUI’s performance.

Prompt engineering enables customized analysis strategies. For example, a prompt that checks ICUI’s liquidity ratios can instantly generate a report, helping investors fine‑tune their risk profile on the fly.